Laura F. Newell

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes et al. · Journal of Clinical Oncology · 2018 · 990 citations · Full text

Medicine, Oncology, Pharmacology +15

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia

Alyssa Carey, David K. Edwards, Christopher A. Eide et al. · Cell Reports · 2017 · 270 citations · Full text

Life Sciences, Cell Biology, Oncology +17

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

Jeffrey E. Lancet, Geoffrey L. Uy, Laura F. Newell et al. · The Lancet Haematology · 2021 · 211 citations

Medicine, Geriatric Medicine, Oncology +14

BMPs signal alternately through a SMAD or FRAP–STAT pathway to regulate fate choice in CNS stem cells

Prithi Rajan, David M. Panchision, Laura F. Newell et al. · The Journal of Cell Biology · 2003 · 206 citations · Full text

Life Sciences, Cell Biology, Developmental Biology +17

Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.

Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes et al. · Journal of Clinical Oncology · 2016 · 164 citations

Medicine, Oncology, Pharmacology +13